Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Average Rating of “Buy” by Brokerages

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has earned an average recommendation of “Buy” from the eleven ratings firms that are presently covering the stock, MarketBeat Ratings reports. Eleven investment analysts have rated the stock with a buy rating. The average 1 year target price among analysts that have covered the stock in the last year is $64.44.

JSPR has been the topic of several research analyst reports. Royal Bank of Canada decreased their price target on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a research note on Thursday, January 9th. UBS Group started coverage on shares of Jasper Therapeutics in a report on Thursday, February 13th. They issued a “buy” rating and a $38.00 price objective on the stock. JMP Securities restated a “market outperform” rating and issued a $70.00 price objective on shares of Jasper Therapeutics in a report on Monday, January 6th. HC Wainwright cut their price objective on shares of Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating on the stock in a report on Friday, January 10th. Finally, BMO Capital Markets started coverage on shares of Jasper Therapeutics in a report on Friday, December 6th. They issued an “outperform” rating and a $63.00 price objective on the stock.

Jasper Therapeutics Price Performance

JSPR opened at $5.80 on Thursday. Jasper Therapeutics has a one year low of $4.55 and a one year high of $31.01. The company’s 50 day simple moving average is $10.28 and its 200-day simple moving average is $16.91. The stock has a market capitalization of $87.01 million, a P/E ratio of -1.22 and a beta of 2.11.

Institutional Investors Weigh In On Jasper Therapeutics

Hedge funds have recently bought and sold shares of the company. Jane Street Group LLC acquired a new stake in Jasper Therapeutics in the third quarter worth $251,000. Samsara BioCapital LLC raised its holdings in Jasper Therapeutics by 11.4% in the third quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock worth $10,997,000 after purchasing an additional 59,642 shares during the period. Barclays PLC raised its holdings in Jasper Therapeutics by 320.7% in the third quarter. Barclays PLC now owns 16,146 shares of the company’s stock worth $304,000 after purchasing an additional 12,308 shares during the period. Wellington Management Group LLP acquired a new stake in Jasper Therapeutics in the third quarter worth $447,000. Finally, Ally Bridge Group NY LLC raised its holdings in Jasper Therapeutics by 82.7% in the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock worth $7,514,000 after purchasing an additional 180,852 shares during the period. 79.85% of the stock is currently owned by institutional investors and hedge funds.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.